TABLE 2.

IP-10 levels during the initial 12 months of antiretroviral treatment in 112 HIV+ study participants^a

	IP-10 (pg/ml)
Participant sample	Baseline	M1	M3	M6	M12
All participants	634 (436–971) n = 112	340 (236–582) n = 112	226 (145–342) n = 96	176 (127–300) n = 77	189 (117–302) n = 68
VRs
All	650 (428–1,002) n = 91	337 (235–574) n = 91	218 (142–339) n = 78	165 (126–243) n = 68	159 (112–262) n = 51
TB+	1,106 (627–1,704) n = 17	472 (307–737) n = 17	263 (189–670) n = 14	194 (148–333) n = 15	191 (132–213) n = 12
TB-	628 (391–885) n = 74	300 (215–515) n = 74	206 (136–317) n = 64	155 (125–231) n = 53	152 (105–269) n = 39
VNRs	557 (441–878) n = 21	406 (236–646) n = 21	253 (200–351) n = 18	319 (185–533) n = 9	343 (184–568) n = 17

^aData presented as median (IQR). IP-10, interferon-γ-inducible protein 10; M, month after ART initiation; VRs, virological responders; VNRs, virological nonresponders; TB, tuberculosis.